The week of May 12, 2025, featured several executive actions that bear directly on the independence of federal regulatory agencies. The most significant is Executive Order 14297—Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, published in two tracked versions (Federal Register). This order directs the HHS Secretary to "propose a rulemaking plan to impose most-favored-nation pricing" and empowers the FDA Commissioner to "review and potentially modify or revoke approvals granted for drugs" as a pricing enforcement mechanism. It further instructs the Attorney General and FTC Chairman to "undertake enforcement action," converting traditionally independent enforcement decisions into executive directives. The administration's stated justification is improving drug affordability for American patients—a goal with broad public support. Separately, Fighting Overcriminalization in Federal Regulations requires all agencies—including independent ones—to catalog criminal regulatory offenses and submit them to OMB, subjects new strict-liability rulemakings to OIRA review, and declares that criminal enforcement of unreported offenses "is strongly discouraged." The administration frames this as improving fairness and transparency in regulatory enforcement—goals that also command bipartisan intellectual support.

This pattern may matter because it could erode the FDA's capacity to make drug approval and revocation decisions on scientific and safety grounds alone—an institutional separation established by the 1962 Kefauver-Harris Amendments specifically to prevent political interference in efficacy determinations. When drug approval status is wielded as leverage for pricing negotiations, the boundary between safety regulation and economic policy may blur, potentially compromising public trust in the drug approval process itself.

A plausible benign reading of EO 14297 is that it is a negotiating posture: presidents routinely issue maximalist executive orders on drug pricing to signal urgency, and the order's operative provisions are hedged with "to the extent consistent with law" language that may limit actual agency action. The FDA revocation provision could be read as directing review of approval pathways (such as expedited approvals with limited evidence), not as threatening to pull safe drugs from the market for pricing reasons—a distinction that matters legally even if the rhetorical framing is aggressive. A further interpretation is that FTC enforcement coordination is not novel; presidents have long directed interagency coordination, and the order may simply formalize existing policy channels rather than override independent judgment. Additionally, the executive orders might be intended to streamline and enhance transparency in regulatory processes, which could be viewed as a positive reform effort. However, the explicit linkage of approval revocation to pricing leverage is textually clear and appears to lack obvious precedent in prior drug pricing executive orders, though a comprehensive precedent review was not conducted, which limits the certainty of this observation.

Regarding the overcriminalization order, a strong counter-argument is substantive: strict-liability criminal offenses in federal regulation have been criticized across the political spectrum for decades, and requiring agencies to catalog and justify them is a defensible reform with bipartisan intellectual pedigree. The concern lies not in the policy goal but in the mechanism—requiring independent agencies to submit rulemakings to OIRA review and discouraging enforcement of offenses not reported to OMB concentrates enforcement discretion in the executive. A second alternative explanation is that this order may face legal challenges and thus represents aspirational policy rather than operative constraint on agencies. Nonetheless, the practical chilling effect on agency enforcement during the reporting period is real regardless of eventual legal outcomes.

On the legislative side, the Bureau of Consumer Financial Protection Commission Act proposes restructuring the CFPB from a single-director to a commission-led agency. Restructuring to a commission model is not inherently erosive—indeed, many independent agencies use this structure, and such a change could enhance decision-making by incorporating diverse perspectives. But the context of ongoing executive efforts to expand White House control over independent agencies makes the timing noteworthy. Senator Markey's floor speech on DOE deregulation documents the Department of Energy's simultaneous elimination of 47 regulations, described as the "largest deregulatory effort in the Department of Energy's history." While deregulation is a legitimate policy choice, mass regulatory rollback of this scale raises procedural questions about whether individual notice-and-comment requirements under the Administrative Procedure Act are being observed.

Limitations: This analysis is based on AI review of published documents and does not reflect non-public implementation guidance, agency responses, or legal challenges that may constrain operative effect. The two "clearly concerning" documents are versions of a single executive order, which concentrates the evidentiary base. Floor speeches represent one senator's characterization of DOE actions, not independently verified accounts. The observation regarding lack of precedent for linking approval revocation to pricing leverage has not been exhaustively verified.